Switzerland: Spexis, a SIX-listed clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, has received a capital commitment totalling US$2.5m with participation from SPRIM Global Investments (SGI)…
Switzerland: Spexis, a SIX-listed clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, has received a capital commitment totalling US$2.5m with participation from SPRIM Global Investments (SGI)…
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference